Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
1(7%)
Results Posted
92%(11 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
4
27%
Ph phase_2
6
40%
Ph phase_3
4
27%

Phase Distribution

4

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
4(28.6%)
Phase 2Efficacy & side effects
6(42.9%)
Phase 3Large-scale testing
4(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(12)
Terminated(1)
Other(1)

Detailed Status

Completed12
unknown1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
92.3%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (28.6%)
Phase 26 (42.9%)
Phase 34 (28.6%)

Trials by Status

completed1280%
unknown17%
active_not_recruiting17%
terminated17%

Recent Activity

1 active trials
Showing 5 of 15
terminatedphase_2

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
completedphase_2

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

NCT04765384
completedphase_3

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
completedphase_1

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
completedphase_3

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

NCT04908722
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT05000216Phase 2

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Terminated
NCT04765384Phase 2

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

Completed
NCT05091307Phase 3

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

Completed
NCT04889209Phase 1

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Completed
NCT04908722Phase 3

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

Completed
NCT05007080Phase 2

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive

Completed
NCT04436276Phase 1

A Study of Ad26.COV2.S in Adults (COVID-19)

Completed
NCT04505722Phase 3

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

Completed
NCT04999111Phase 2

A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2

Completed
NCT04614948Phase 3

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

Completed
NCT05409261Phase 2

Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

Active Not Recruiting
NCT04535453Phase 2

A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents

Completed
NCT04894305Phase 1

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

Completed
NCT04509947Phase 1

A Study of Ad26.COV2.S in Adults (COVID-19)

Completed
NCT04817657

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

Unknown

All 15 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
15